Figure 1From: A single dose of pegfilgrastim compared with daily filgrastim for supporting neutrophil recovery in patients treated for low-to-intermediate risk acute myeloid leukemia: results from a randomized, double-blind, phase 2 trialKaplan-Meier estimates of time to recovery from severe neutropenia in Induction 1.Back to article page